logo conference-reports

Conference Reports

При финансовой поддержке logo MSD Oncology

ASCO 2019 — Adjuvant pemetrexed-cisplatin offers a safer option for nonsquamous NSCLC

Efficacy similar to that of vinorelbine-cisplatin.